Pavan Pinnamaneni, MD
Family Medicine · Huntington, TXNPI 1336470434
Payments from drug & device makers
Across 381 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- GSK$837
- E.r. Squibb & Sons, L.L.C.$635
- Boehringer Ingelheim$552
- Bayer$412
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,32499%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $1,126 |
| Novo Nordisk | 57 | $1,068 |
| GSK | 48 | $837 |
| E.r. Squibb & Sons, L.L.C. | 38 | $635 |
| Boehringer Ingelheim | 31 | $552 |
| Bayer | 19 | $412 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $404 |
| Novartis | 18 | $288 |
| Pfizer | 15 | $241 |
| Lilly USA, LLC | 15 | $232 |
| Merck | 13 | $187 |
| Johnson & Johnson | 11 | $180 |
| Otsuka America Pharmaceutical, Inc. | 7 | $164 |
| Mylan Specialty L.p. | 6 | $130 |
| Sanofi-aventis U.S. LLC | 4 | $116 |
| Amgen | 7 | $104 |
| Dexcom, Inc. | 4 | $86 |
| Intuitive Surgical | 1 | $75 |
| Exact Sciences | 3 | $60 |
| Viatris Specialty LLC | 2 | $57 |
| Corcept Therapeutics | 2 | $52 |
| Medtronic | 1 | $50 |
| Jazz Pharmaceuticals Inc. | 1 | $48 |
| Amarin Pharma, Inc. | 2 | $41 |
| AbbVie | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Acadia Pharmaceuticals Inc | 1 | $25 |
| Tactile Systems Technology Inc | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Biogen | 1 | $22 |
| Shield Therapeutics Inc | 1 | $20 |
| Abbott | 1 | $20 |
| Radius Health, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$114
How this compares
$7,386 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 192 | $290,001 |
| EliquisApixaban | 180 | $162,242 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 170 | $129,283 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $85,169 |
| XareltoRivaroxaban | 77 | $58,485 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $38,686 |
| MounjaroTirzepatide | 22 | $30,867 |
| JardianceEmpagliflozin | 45 | $28,571 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 30 | $26,406 |
| FarxigaDapagliflozin Propanediol | 44 | $25,595 |
| EntrestoSacubitril/Valsartan | 24 | $24,056 |
| LinzessLinaclotide | 17 | $22,551 |
| Rosuvastatin Calcium | 1,812 | $22,357 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 14 | $21,049 |
| JanuviaSitagliptin Phosphate | 20 | $20,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $1,068 | $311,050206 claims |
| Boehringer IngelheimTrijardy Xr, Jardiance, Synjardy Xr, Glyxambi, Spiriva Respimat | $552 | $202,359278 claims |
| PfizerEliquis | $241 | $162,242180 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $837 | $129,962160 claims |
| Johnson & JohnsonXarelto | $180 | $58,48577 claims |
| AstraZenecaFarxiga, Brilinta | $1,126 | $37,15063 claims |
| Lilly USA, LLCMounjaro | $232 | $30,86722 claims |
| NovartisEntresto | $288 | $24,05624 claims |
| AbbVieLinzess | $35 | $22,55117 claims |
| MerckJanuvia | $187 | $20,35420 claims |
| BayerKerendia | $412 | $8,97513 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $7,021642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Huntington
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.